Big banks benefiting from boom in data center construction, as they can accommodate capital needs of hyperscalers & have investment banking arms that can run securitization offerings.
Examine the MCA 2026 syllabus: a thorough overview of the essential subjects, broken down by semester, and highlighting popular specializations like artificial intelligence and cloud computing in ...
Data center developer Stack Infrastructure announced yesterday that it would be adding 121MW of capacity to its campus outside Portland, Oregon. Although the news of the expansion was announced by ...
The company this week announced it has broken ground on the second data center at its Inzai campus, adding a standalone 18MW building to the existing 18MW facility. Delivery of TKYO1B is expected in ...
The breach happened in October, but was detected by Substack on February 3rd. The breach happened in October, but was detected by Substack on February 3rd. is a news writer focused on creative ...
SAN FRANCISCO--(BUSINESS WIRE)--ClickHouse, Inc., the company behind the world’s fastest real-time analytical database, announced a high-performance, enterprise-grade Postgres service natively ...
We introduce VeriStruct, a novel framework that extends AI-assisted automated verification from single functions to more complex data structure modules in Verus. VeriStruct employs a planner module to ...
Many engineering teams still rely on architecture optimized for transactional apps, not for AI systems that mix structured and unstructured data and live event streams. This legacy architecture has ...
A Colorado-based company, Stack Infrastructure, plans to build a new data center in New Albany, Ohio. The new 300,000-square-foot facility will be built next to the company's existing data center.
Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to set their weight loss assets apart in an increasingly crowded field as ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results